This funding will support the development and commercialization of our supervised AI-driven platform aimed at enhancing Deep Brain Stimulation (DBS) procedures for Parkinson’s Disease. The investment will help us expand globally, particularly in Europe and the US, and continue our innovations in neurosurgery.
Read the full article in French here.
An English translation by Google is available here.
At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...
Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...
An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...